Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2013 June;55(2) > Panminerva Medica 2013 June;55(2):175-89

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

PANMINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6


eTOC

 

  CUTTING EDGE RESPIRATORY MEDICINE 2013


Panminerva Medica 2013 June;55(2):175-89

language: English

Treatment of sarcoidosis

Baughman R. P.

Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA


PDF  


The treatment of pulmonary sarcoidosis is based on several factors. These include changes in pulmonary physiology, presence of extra-pulmonary disease, and symptoms. Several immunosuppressive agents have been studied and recommendations regarding the utility of these different agents have evolved. While glucocorticoids remain the most commonly used agent, other drugs have been used as steroid sparing and for those patients who progress despite routine treatment. Non immunosuppressive agents also play a role in the therapy of pulmonary sarcoidosis patients. These include treatments for pulmonary hypertension, infection, and fatigue.

top of page

Publication History

Cite this article as

Corresponding author e-mail

bob.baughman@uc.edu